Company Description
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology.
The company’s product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi.
The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014.
Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Michael M. Rowe |
Contact Details
Address: 295 Madison Avenue, Suite 2400 New York, New York 10017 United States | |
| Phone | 813-766-9539 |
| Website | eyenovia.com |
Stock Details
| Ticker Symbol | EYEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001682639 |
| CUSIP Number | 30234E104 |
| ISIN Number | US30234E1047 |
| Employer ID | 47-1178401 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael M. Rowe | Chief Executive Officer and Director |
| Dr. Tsontcho Ianchulev M.D., M.P.H., MPH | Co-Founder and Executive Chairman |
| John P. Gandolfo CPA | Chief Financial Officer and Secretary |
| Bren Kern | Chief Operating Officer and Corporate Vice President |
| Alexander Lobo | Investor Contact |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jul 5, 2024 | 8-K | Current Report |
| Jul 1, 2024 | 424B3 | Prospectus |
| Jul 1, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 424B5 | Filing |
| Jun 14, 2024 | 8-K | Current Report |
| Jun 4, 2024 | 8-K | Current Report |
| May 16, 2024 | 424B5 | Filing |
| May 16, 2024 | 8-K | Current Report |
| May 15, 2024 | 8-K | Current Report |